Meritage Portfolio Management Supernus Pharmaceuticals, Inc. Transaction History
Meritage Portfolio Management
- $1.56 Billion
- Q4 2024
A detailed history of Meritage Portfolio Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Meritage Portfolio Management holds 48,181 shares of SUPN stock, worth $1.89 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
48,181
Previous 44,295
8.77%
Holding current value
$1.89 Million
Previous $1.38 Million
26.14%
% of portfolio
0.11%
Previous 0.08%
Shares
16 transactions
Others Institutions Holding SUPN
# of Institutions
284Shares Held
60.5MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$407 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$240 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$200 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$113 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$103 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.09B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...